Announcement
26 March 2024

Share your personal experience – the impact of drug resistance on cancer care outcomes

Personal experiences are invaluable in driving home the degree to which drug-resistant infections can severely complicate effective cancer treatment, and the pressing need for effective solutions.

UICC is seeking to hear from individuals who have navigated the complexities of cancer and drug-resistant infections.

One in five people undergoing treatment for cancer are hospitalised due to infection and such personal experiences are invaluable in driving home the degree to which drug-resistant infections can severely complicate, or even prevent, effective cancer treatment, deeply affecting patient outcomes and quality of life. 

Whether it involves enduring a prolonged fight against an infection, adjusting treatment plans to overcome these challenges, or the emotional toll, these experiences can contribute to a wider understanding of the consequences of AMR and highlight the pressing need for effective solutions.

Individuals willing to share their journey of dealing with drug-resistant infections while undergoing cancer treatment are encouraged to reach out at advocacy@uicc.org.

By sharing, individuals can help UICC inspire action, advocate for change, and highlight the necessity of incorporating AMR mitigation strategies into cancer treatment and care protocols worldwide.

Click here for more information on antimicrobial resistance and its impact on cancer care

 

Last update

Monday 22 July 2024

Share this page

Related content

Asian man wearing a mask looking into a lab microscope

Looking ahead towards the UN high-level meeting on antimicrobial resistance, Michael Craig describes the impact of antimicrobial resistance on people living with cancer, and underscores the actions needed to address this threat. 

A Black woman with cancer sorts her pills at the kitchen table

A new series of papers by The Lancet released on 23 May 2024 sheds light on the significant impact of antimicrobial resistance (AMR) on global health and cancer treatment, particularly in low- and middle-income countries.